电镀镍污泥氨浸出工艺中氨回收的技术

介绍了电镀镍污泥浸出工艺中氨回收的工艺流程、使用原材料和各单元操作,并对各单元操作的技术条件进行了理论分析和实践检验.     

The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib

Introduction Anaplastic lymphoma kinase (ALK) targeting drugs provide an important option for advanced non-small cell lung cancer patients with this distinct tumor type; however, there is considerable uncertainty as to which drug provides the optimal value after crizotinib treatment. This study estimated the cost-utility of alectinib vs ceritinib from a US payer perspective.

Methods A cost-utility model was developed using partition survival methods and three health states: progression-free (PF), post-progression (PP), and death. Survival data were derived from the key clinical trials (alectinib: NP28761 &; NP28673, ceritinib: ASCEND I and II). Costs included drugs, adverse events, and supportive care. Utilities were based on trial data and the literature. One-way and probabilistic sensitivity analyses (PSA) were performed to assess parameter uncertainty.

Results Treatment with alectinib vs ceritinib resulted in increases of 2.55 months in the PF state, 0.44 quality adjusted life-years (QALYs), and $13,868, yielding a mean cost/QALY of $31,180. In the PSA, alectinib had a 96% probability of being cost-effective at a willingness-to-pay of $100,000/QALY. Drivers of model results were drug costs and utilities in the PF health state. The ICER ranged from $10,600–$65,000 per QALY in scenario analyses, including a sub-group analysis limited to patients with prior chemotherapy and crizotinib treatment.

Conclusions Treatment with alectinib in ALK?+?crizotinib-treated patients increased time progression-free and QALYs vs ceritinib. The marginal cost increase was driven by longer treatment durations with alectinib. This model demonstrates that alectinib may be considered a cost-effective treatment after progression on crizotinib.     

硒拮抗氟引起肺脏、脾脏损伤中肥大细胞变化的观察

采用Wistar大鼠50只分别饮用含氟化钠150mg/L和含氟化钠150mg/L加不同剂量亚硒酸钠水.二个月后断头处死,取肺,脾作肥大细胞(MC),糖元PAS反应,DNA(Feulgen)反应观察.结果:肺,脾氟化钠(150mg/L)组肥大细胞与正常组比较,无明显变化.糖元PAS反应,DNA(Feulgen)反应减弱;氟化钠(150mg/L)加亚硒酸钠(2.0mg/L)组,肥大细胞显著增加,糖元PAS反应,DNA(Feulgen)反应程度增强.提示:硒在保护氟引起肺,脾损伤过程中,可能对肺、脾的肥大细胞增生和活化起促进作用.     

一种太阳能电池片胶带全自动贴付设备的设计

介绍了一种太阳能电池片胶带全自动贴付机的具体设计方案,设备在经过一段时间的试生产后达到了预期的设计效果。     

基于ICOS PVI-6系统的太阳能电池质量控制研究

自动摄像系统ICOS PVI-6能跟踪太阳能电池在丝网印刷制作正面电极的过程,研究各种印刷质量问题造成的电性能变化趋势。本试验以156mm×156mm多晶P型硅片为例,启动PVI-6系统,进行识别太阳能电池正面银电极的断线条数,当监控到断线的印刷质量问题后在生产过程中及时擦拭网版、调整印刷参数,后使用Berger分类检测系统测试试验电池片的电性能,与未使用监控系统的情况进行比较,电池片的电性能得到了明显提高。     

结核分枝杆菌诱导抗原提呈细胞Toll样受体表达差异性研究进展

该文结核分枝杆菌感染后,抗原提呈细胞表面Toll样受体(toll-like receptors,TLR)表达差异、抗原提呈细胞的增殖、分化以及相关信号通路作一阐述.     

Role of transfusion in stem cell transplantation: a freedom-from-transfusion (FFT), cost and survival analysis

Abstract

Background: Transfusion of blood products is often necessary for patients undergoing stem cell transplantation (SCT). The need for red cell and platelet transfusion may vary significantly depending on the type of transplantation and underlying disease.

Methods: In an attempt to evaluate the need and volume of transfusions in patients undergoing SCT at University of Kansas Medical Center, the authors retrospectively evaluated the transfusion data of all patients who received SCT between 2000 and 2005.

Results: A total of 138 (90%) out of 154 patients undergoing autologous SCT and 24 (43%) out of 56 patients with allogeneic SCT exhibited total hematopoietic engraftment and freedom from transfusion (FFT). Time to achieve FFT (median; range) for RBC units for autologous SCT (12; 0–183) was significantly shorter compared with allogeneic SCT (16.5; 0–373). Number of RBC units (median; range) transfused were significantly less in patients undergoing autologous SCT (4; 0–26) compared to patients undergoing allogeneic SCT (6.5; 0–54). The median cost of transfusion was significantly higher in patients undergoing allogeneic SCT (red cell: $2,015; platelet: $4,480) compared to patients undergoing autologous SCT (red cell: $1,240; platelet: $2,520). The authors recognize that this was a retrospective single-center study and practice guidelines may vary from center to center.

Conclusion: Authors conclude that transfusion of blood products is an expensive but integral part of SCT, more so for allogeneic SCT than for patients undergoing autologous SCT. Total FFT is a desirable long-term goal of successful marrow transplantation.     

动物对温度适应的分子生物学研究进展

动物对环境温度的适应,会使自身的细胞内转录和表达模式发成变化,以适合环境的变化,此时它会出现新的基因开放和新蛋白因子的合成,这总的来说是动物对自身的一种保护方式。本文从基因水平、蛋白质水平、细胞膜水平等三个方面综述了动物对环境温度适应的研究概况,并讨论了动物对环境温度适应的分子生物学机制以及在进化中的意义。     

生物气固体氧化物燃料电池研究进展

对近年来国内外生物气固体氧化物燃料电池发电领域的研究进行了归纳分析。在介绍生物气产生和氧离子型固体氧化物燃料电池产电原理的基础上，总结了固体氧化物燃料电池以生物质产出的生物气为燃料发电所涉及的电化学反应；介绍了国外研究者对该类发电过程进行的试验和模拟研究；同时，对生物气结合固体氧化物燃料电池的研究进展进行了分析。得出的结论为，生物气结合固体氧化物燃料电池进行产电具有重大的实际和环保意义。     

On regulations for 5G: Micro licensing for locally operated networks

Future 5G networks aim at providing new high-quality wireless services to meet stringent and case-specific needs of various vertical sectors beyond traditional mobile broadband offerings. 5G is expected to disrupt the mobile communication business ecosystem and open the market to drastically new sharing based network operational models. 5G technical features of network slicing and small cell deployments in higher carrier frequencies will lower the investment barrier for new entrants to deploy local radio access networks and offer vertical specific services in specific areas and allow them lease the remaining required infrastructure on demand from mobile network operators (MNO) or infrastructure vendors. To realize the full vision of 5G to benefit the society and promote competition, innovation and emergence of new services when the 5G end-to-end network spans across different stakeholders administrative domains, the existing regulations governing the mobile communication business ecosystem are being refined. This paper provides a tutorial overview on how 5G innovations impact mobile communications and reviews the regulatory elements relevant to 5G development for locally deployed networks. This paper expands the recent micro licensing model for local spectrum authorization in future 5G systems and provides guidelines for the development of the key micro licensing elements. This local micro licensing model can open the mobile market by allowing different stakeholders to deploy local small cell networks with locally issued spectrum licenses ensuring pre-defined quality guarantees for the vertical sectors’ case specific needs.